AzTrials
AzTrials

Preterm Premature Rupture of Fetal MembranesNCT02125708

Core-temperature Monitoring in Patients With PPROM

A study testing OvulaRing® in people with Preterm Premature Rupture of Fetal Membranes, run by Medical University of Vienna at 1 site in Austria.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The most common reason for preterm prelabor rupture of membrane (PPROM) is an ascendance of infection. Moreover PPROM is one of the main risk factors for chorioamnionitis. PPROM-related morbidity and mortality is higher in the neonate than in the mother, especially in case of intrauterine inflammation. Read more about this study

Who is it for?
Ages 18 to 60 years, women onlyHealthy volunteers can take part
What is being tested?
OvulaRing®
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteAustria
Study dates
Jan 2017to Jan 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • single pregnancy
  • verified PPROM
  • gestation week 22 to 27
  • signed informed consent (ICF)

Who cannot join

  • multiple pregnancy
  • Patient's age under 18 years
  • Allergy to epoxide resin or ethylene vinyl acetate (EVA)-Copolymer

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Department of Obstetrics and Gynecology, Medical University of Vienna

    Vienna, 1090

Other trials in Austria

About this study

Official title: Core-temperature Monitoring in Patients With PPROM for Early Detection of Chorioamnionitis - a Pilot Study

The most common reason for preterm prelabor rupture of membrane (PPROM) is an ascendance of infection. Moreover PPROM is one of the main risk factors for chorioamnionitis.

PPROM-related morbidity and mortality is higher in the neonate than in the mother, especially in case of intrauterine inflammation. Of note, the most common biomarkers like CRP and leucocytes are not specific for uterine infections and have not been proven useful in these particular cases. Studies in intensive care medicine could show that there is a possible correlation between onset of infection and body-core-temperature.

Read more

The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility.

Twenty patients with verified PPROM between gestation week 22 and 27 should be included in this study. After gynecological and physical examination within verification of PPROM women will be informed and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.

The investigators aim to describe a possible correlation between core-temperature and common biomarkers in clinical use for the detection of chorioamnionitis in patients with PPROM to possibly assess the optimal time for delivery subsequently.

Read the detailed description

Introduction A prelabor rupture of membranes (PROM) is defined as a loss of amniotic fluid within a rupture of amniotic membrane before the onset of labour, as preterm prelabor rupture of membranes (PPROM) refers to PROM before 37+0 weeks of gestation.

PPROM occurs in 3 percent of pregnancies and is associated with one third of preterm births. There are multiple risk-factors for PPROM as maternal physiologic, genetic, and environmental as well as life-style factors. Of note, history of PPROM in a previous pregnancy, antepartum bleeding, cigarette smoking and genital tract infections, as the single most identifiable risk factor, are strongly associated with PPROM.

PPROM is diagnosed by the clinical loss of fluid from the cervical os. In case of not immediately visible amniotic fluid loss during the gynecological inspection, it can be diagnosed by ultrasound and verified by tests like the Amnisure© or the Fertisave© which detect the alpha microgloubulin 1 or the IGF binding protein of the fetal membranes.

Referring to a randomized controlled trial, the majority of pregnancies with PPROM deliver within one week of membrane rupture.

PPROM-related morbidity and mortality, which depends on gestational age, is higher in the neonate than in the mother, especially in case of intrauterine inflammation. Pulmonary hypoplasia, facial and orthopedic deformation can be the cause of prolonged, early PPROMS.

As the incidence of infection is higher at earlier gestational ages, up to one third of women with PPROM develop serious infections, including chorioamnionitis, endometritis and septicemia. Responsible bacterias are enterococcus, staphylococcus or anaerobic species.

The goal of antibiotic prophylaxis/therapy in PPROM is to reduce maternal and neonatal morbidity and mortality. Women should be observed for signs of infection, including maternal temperature, fetal heart rate, uterine contractions, and periodically common clinical infection markers. As the most common biomarkers like CRP and leucocytes are not specific for uterine infections, they have not been proven useful in these particular cases.

Prematurity is the crucial risk to the fetus with PPROM in the absence of complications like infection, before 34 weeks of gestation. Therefore, expectative management of uncomplicated PPROM-pregnancies at this gestational age is routinely used. This includes blood cell and infection monitoring, avoiding vaginal manipulation, antibiotic prophylaxis/treatment and corticosteroids.

After having reached gestational week 34+ induction of labour is routinely performed, without induction of lung maturity. The goal is a quick reaction to a chorioamnionitis with a prompt delivery.

Materials and Methods This study is conducted as a single centre pilot study in patients with PPROM. The study was approved by the local ethics committee of the Medical University of Vienna (IRB number: 1031/2014). Study center is the Department of Obstetrics and Gynecology of the Medical Universitiy of Vienna General Hospital.

Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.

The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensored thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.

As there is no change of common PPROM-therapy, only clinical standard parameters will lead to the termination of pregnancy. Directly before delivery the OvulaRing® will be removed and the sensor-data will be analyzed with a special software.

Hypothesis In this pilot study, the investigators aim to describe a possible correlation between core-temperature and common biomarkers in clinical use for the detection of chorioamnionitis in patients with PPROM to possibly assess the optimal time for delivery.

A correlation between temperature and CRP, leucocytes and IL-6 should be explored. Later on, these facts may be used to optimize the standard procedures for a PPROM.

In some studies there is pointed out that there is a need for new parameters for chorioamnionitis. Maybe temperature monitoring can become such a new biomarker.

Being tested
OvulaRing®
Keywords
preterm prelabor rupture of membranes, Ovula Ring, body-core-temperature, biomarkers, Single pregnancies, PPROM, gestation week 22 and 27
Medical subject headings
Fetal Membranes, Premature Rupture, Preterm Premature Rupture of the Membranes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OvulaRing®Device

    The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.

Study groups in NCT02125708
Study groupRoleWhat they receive
OvulaRing®OtherTwenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
Receives: Device: OvulaRing®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body-core-temperature

    The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.

    As there is no change of common PPROM-therapy, only clinical standard parameters will lead to the termination of pregnancy. Directly before delivery the OvulaRing® will be removed and the sensor-data will be analyzed with a special software.

    Measured: 288 times a day from PPROM-verification until delivery

Secondary outcomes (3)
  1. CRP

    Measured: once a day from hospitalization due to PPROM until delivery

  2. Interleukine (IL-) 6

    Measured: once a day from hospitalization due to PPROM until delivery

  3. white blood cell count

    Measured: once a day from hospitalization due to PPROM until delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Apr 2014 (estimated)
  2. Study startJan 2017
  3. Primary completionAug 2017 (estimated)
  4. Study completionJan 2018 (estimated)

Why it stopped: no acitve participants

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02125708
Sponsor's protocol ID
0012014
Status last verified
Nov 2016
First submitted
23 Apr 2014
Last updated
26 Feb 2021
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing OvulaRing® in people with Preterm Premature Rupture of Fetal Membranes, run by Medical University of Vienna at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 26 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body-core-temperature (time frame: 288 times a day from PPROM-verification until delivery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in